SAPHNELO® (anifrolumab-fnia): A First-In-Class IFN-1 Signaling Inhibitor, Now With 4-Year Data From a Long-Term Safety and Tolerability Study
Exhibit Hall, Innovation Theater A
Developed and offered by AstraZeneca
(Non-CME)
Exhibit Hall, Innovation Theater A
Developed and offered by AstraZeneca
(Non-CME)
Exhibit Hall, Innovation Theater B
Developed and offered by GSK
(Non-CME)
Exhibit Hall, Innovation Theater A
Developed and offered by Sanofi
(Non-CME)
Exhibit Hall, Innovation Theater B
Developed and offered by GSK
(Non-CME)
Exhibit Hall, Innovation Theater A
Developed and offered by Pfizer, Inc.
(Non-CME)
Exhibit Hall, Innovation Theater B
Developed and offered by Novartis Pharmaceuticals Corporation
(Non-CME)
Exhibit Hall, Innovation Theater A
Developed and offered by Boehringer Ingelheim Pharmaceuticals, Inc.
(Non-CME)
Exhibit Hall, Innovation Theater B
Developed and offered by Janssen
(Non-CME)
Exhibit Hall, Innovation Theater A
Developed and offered by Alexion Pharmaceuticals, Inc.
(Non-CME)
Exhibit Hall, Innovation Theater B
Developed and offered by Kiniksa Pharmaceuticals Corp.
(Non-CME)
Exhibit Hall, Innovation Theater A
Developed and offered by GSK
(Non-CME)
Exhibit Hall, Innovation Theater B
Developed and offered by Aurinia Pharma U.S.
(Non-CME)
Exhibit Hall, Innovation Theater A
Developed and offered by Cabaletta Bio
(Non-CME)
Exhibit Hall, Innovation Theater B
Developed and offered by AstraZeneca
(Non-CME)